DERM Journey Medical Corporation
Debt Financing ·
Journey Medical's $25.0 million SWK term loan now matures June 27, 2028. Principal repayments start in February 2026 unless trailing revenue tops $60.0 million at December 31, 2025.
Journey Medical signed an at-the-market sales agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC for up to 3,750,000 shares. It ended an older B. Riley program under which it had sold 4,121,318 shares.
Journey Medical Corporation is a commercial-stage pharmaceutical company that sells and markets FDA-approved prescription products for dermatological conditions through its field sales organization. Its current portfolio includes eight FDA-approved prescription drugs marketed in the U.S. Emrosi, a minocycline extended-release capsule for inflammatory lesions of rosacea in adults, was approved in November 2024, and the company began sales promotion in April 2025. Its other actively marketed products are Qbrexza, for primary axillary hyperhidrosis, Accutane, for severe recalcitrant nodular acne, and the topical minocycline foams Amzeeq and Zilxi. Legacy products include Exelderm and Targadox. Journey developed Emrosi in collaboration with Dr. Reddy's Laboratories, Ltd. The company acquires rights to products and product candidates by licensing or acquiring an ownership interest, funds their development, and commercializes them. Journey is a controlled subsidiary of Fortress Biotech, Inc.
| Product or program | What it is | Stage |
|---|---|---|
| Emrosi | Minocycline extended-release capsule for inflammatory lesions of rosacea | approved in the US |
| Qbrexza | Medicated cloth towelette for primary axillary hyperhidrosis | approved in the US |
| Accutane | Oral isotretinoin for severe recalcitrant nodular acne | approved in the US |
| Amzeeq | Topical minocycline foam for acne vulgaris | approved in the US |
| Zilxi | Topical minocycline foam for rosacea inflammatory lesions | approved in the US |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $61.9 million | $56.1 million |
| Research and development | $480,000 | $9.9 million |
| Net income (loss) | -$11.4 million | -$14.7 million |
| Cash from operations | -$12.4 million | -$9.1 million |
| Cash and equivalents | $24.1 million | $20.3 million |
Our latest story on this, dated Aug 28, 2025: "Journey Medical sets up new at-the-market program for 3,750,000 shares". The story links the filing or release it is based on. Read the story.
Journey Medical Corporation trades under the ticker DERM on NASDAQ.
Journey Medical Corporation is listed on NASDAQ.
The SEC Central Index Key (CIK) for Journey Medical Corporation is 1867066. Its filings are on SEC EDGAR.
Our directory records Journey Medical Corporation under United States.
Our directory classifies Journey Medical Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Journey Medical Corporation is US48115J1097.
aibio.space lists Journey Medical Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Journey Medical Corporation is a commercial-stage pharmaceutical company that sells and markets FDA-approved prescription products for dermatological conditions through its field sales organization. Its current portfolio includes eight FDA-approved prescription drugs marketed in the U.S. Emrosi, a minocycline extended-release capsule for inflammatory lesions of rosacea in adults, was approved in November 2024, and the company began sales promotion in April 2025.
Emrosi: Minocycline extended-release capsule for inflammatory lesions of rosacea Stage: approved in the US.
Qbrexza: Medicated cloth towelette for primary axillary hyperhidrosis Stage: approved in the US.
$61.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Journey Medical Corporation reported a net loss of $11.4 million for the fiscal year ended Dec 31, 2025, and used $12.4 million of cash in operations, per its annual report to the SEC.
$480,000 in the fiscal year ended Dec 31, 2025, per its annual report.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio